CSBio CSBio

X
[{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progress of the Small Sample Clinical Trial of Ganovo\u00ae and Ritonavir Combination Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to study the effect of interferon beta-1a in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Royal Melbourne Hospital ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Researchers Launch ASCOT Study for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Royal Melbourne Hospital "},{"orgOrder":0,"company":"Defence Materials Technology Centre","sponsor":"Certara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Defence Materials Technology Centre"},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New study identifies drugs that are safe to use in COVID-19 treatment\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kings College London"},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kings College London"},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Dimerix"},{"orgOrder":0,"company":"Octapharma","sponsor":"University of California San Diego School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Octapharma"},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Announces Promising Interim Results for ZingiVir\u2013H Among COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Undisclosed","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Pankajakasthuri Herbal Research Foundation"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Reports Positive Data from octagam\u00ae Usage in Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Octapharma"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Vopec Pharmaceuticals"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Investigator-Initiated Trial at Kaiser Permanente to Study VASCEPA\u00ae in Reducing Viral Upper Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Amarin"},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Declares Final Clinical Trials of ZingiVir-H as Adjunct Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Undisclosed","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Pankajakasthuri Herbal Research Foundation"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Vaccine","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Kamada"},{"orgOrder":0,"company":"Radboud University","sponsor":"Hellenic Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elderly People Protected Against Respiratory Infections by Bcg Vaccine Reveals Radboud University Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Radboud University"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthritis Drugs May Reduce Mortality and Time in ICU for Sickest Covid Patients- Reports Imperial College","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Imperial College London"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Full-Dose Blood Thinners Decreased Need for Life Support and Improved Outcome in Hospitalized COVID-19 Patients- NIH Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"National Institutes of Health"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Says Remdesivir Likely to be Effective Against New COVID-19 Strains","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPDATE 1-EU Drug Watchdog to Weigh in On Extended Use for Remdesivir by Summer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Evaluating Use of Veklury in Covid-19 Patients Not Requiring Supplemental Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Gilead Sciences"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARPAC Clinical Trial of Leukine in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARPAC Clinical Trial of Leukine\u00ae in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Partner Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Nabs FDA Nod for More Convenient Rework of Antibiotic Orbactiv","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Melinta Therapeutics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Statement on Phase 3 Veklury\u00ae (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Gilead Sciences"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine in High-risk Non-hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Randomized Trial of Leukine\u00ae (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Partner Therapeutics"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmoheal\u2122\/ Artiveda\u2122 Is Clinically Active Against Mild and Moderate Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncotelic Therapeutics"},{"orgOrder":0,"company":"AiPharma","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.A.E","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AiPharma"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Concludes Study on COVID Drug Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Announces Start of TPOXX\u00ae Post-Exposure Prophylactic (\u201cPEP\u201d) Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SIGA Technologies"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Several New Studies Presented at ECCMID 2022 Confirm Veklury\u00ae (Remdesivir) Activity in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Gilead Sciences"},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja\u00ae (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Shionogi"},{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"AIDS Clinical Trials Group"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Shingrix Data Demonstrate 100% Vaccine Efficacy in the Prevention of Shingles in Adults Aged 50 and Over in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"GSK"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            GSK

            Contact Supplier
            • Development Update

            Details:

            Shingrix (recombinant zoster vaccine – RZV) is a non-live, recombinant sub-unit vaccine indicated for the prevention of herpes zoster (HZ) in adults aged 50 and over.

            Lead Product(s): Guaifenesin,Adjuvanted Recombinant Zoster Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Shingrix

            Highest Development Status: Phase IV Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            AIDS Clinical Trials Group

            Contact Supplier
            • Development Update
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C treatment.

            Lead Product(s): Sofosbuvir,Velpatasvir

            Therapeutic Area: Infections and Infectious Diseases Product Name: ACTG 5360

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cefiderocol Sulfate Tosylate has a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens. Fetroja achieved clinical cure in 63% of patients with Acinetobacter baumannii infections and 63% of patients with Pseudomonas aeruginosa infections.

            Lead Product(s): Cefiderocol sulfate tosylate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            New Post-hoc Analysis of Non-Hospitalized COVID-19 Patients in the Phase 3 PINETREE Study Demonstrates Veklury Treatment Initiated Within 5 Days of Symptoms Reduced Risk for Hospitalization by 90%.

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.

            Lead Product(s): Tecovirimat

            Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership between Appili and AiPharma will include the formation of a joint scientific committee to further coordinate clinical and regulatory activities for global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral.

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Appili Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Glenmark’s PMS study is the first and largest post marketing study conducted in India on Favipiravir in mild to moderate COVID-19 patients.

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: FabiFlu

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19).

            Lead Product(s): Artemisinin

            Therapeutic Area: Infections and Infectious Diseases Product Name: PulmoHeal

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Safety and efficacy of inhaled sargramostim for the treatment of COVID-19 has not been established and sargramostim is not approved for treatment of COVID-19. Sargramostim has a different mechanism of action from recombinant G-CSFs products and data should not be extrapolated.

            Lead Product(s): Sargramostim

            Therapeutic Area: Infections and Infectious Diseases Product Name: Leukine

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This study will evaluate the role of Leukine in reducing progression and need for hospitalization in COVID-19 patients. Primary study endpoints are: COVID-19-related emergency room visit, COVID-19- related hospitalization, or death.

            Lead Product(s): Sargramostim

            Therapeutic Area: Infections and Infectious Diseases Product Name: Leukine

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY